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Background: Meta-analysis of randomized trials has shown that postoperative radiotherapy (PORT) had a
detrimental effect on overall survival (OS) in patients with resected N1 non–small cell lung cancer (NSCLC).
Conversely, the locoregional recurrence (LR) rate is reported to be high without adjuvant PORT in these patients.
We have evaluated the pattern of failure, actuarial risk and risk factors for LR in order to identify the subset of N1
NSCLC patients with the highest risk of LR. These patients could potentially benefit from PORT.
Methods: We conducted a retrospective study on 199 patients with pathologically confirmed T1–3N1M0 NSCLC
who underwent surgery. None of the patients had positive surgical margins or received preoperative therapy or
PORT. The median follow-up was 53.8 months. Complete mediastinal lymph node (MLN) dissection and examination
was defined as ≥3 dissected and examined MLN stations; incomplete MLN dissection or examination (IMD) was
defined as <3 dissected or examined MLN stations. The primary end point of this study was freedom from LR (FFLR).
Differences between patient groups were compared and risk factors for LR were identified by univariate and
multivariate analyses.
Results: LR was identified in 41 (20.6%) patients, distant metastasis (DM) was identified in 79 (39.7%) patients
and concurrent LR and DM was identified in 25 (12.6%) patients. The 3- and 5-year OS rates in patients with
resected N1 NSCLC were 78.4% and 65.6%, respectively. The corresponding FFLR rates were 80.8% and 77.3%,
respectively. Univariate analyses identified that nonsmokers, ≤23 dissected lymph nodes, visceral pleural invasion and
lymph node ratio >10% were significantly associated with lower FFLR rates (P < 0.05). Multivariate analyses further
confirmed positive lymph nodes at station 10 and IMD as risk factors for LR (P < 0.05). The 5-year LR rate was highest in
patients with both these risk factors (48%).
Conclusions: The incidence of LR in patients with surgically resected T1–3N1M0 NSCLC is high. Patients with IMD and
positive lymph nodes at station 10 have the highest risk of LR, and may therefore benefit from adjuvant PORT. Further
investigations of PORT in this subset of patients are warranted.
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Surgery is the cornerstone of treatment for early-stage
non–small cell lung cancer (NSCLC). Due to high recur-
rence rates following tumor resection, including radical
surgery, studies have been carried out on the efficacy of
adjuvant therapy. Several randomized trials and meta-
analyses have confirmed that platinum-based adjuvant
chemotherapy can improve overall survival (OS) in pa-
tients with stage II and IIIA NSCLC [1-4]; however, the
role of postoperative radiotherapy (PORT) remains con-
troversial. Although studies have found that PORT can
reduce locoregional recurrence (LR), no survival benefit
was observed. Moreover, meta-analyses of randomized
trials and retrospective studies have reported that PORT
had a detrimental effect on OS in patients with N0 and
N1 NSCLC, despite being beneficial in patients with N2
disease [5-8]. As a consequence, PORT is often recom-
mended for patients with resected pathological N2 dis-
ease, but not for those with N0 or N1 disease. However,
these studies may have been compromised by limitations
such as flaws in the study design and outdated radiation
techniques.
The reported crude risk of LR for resected N1 disease
is high [9-11], which suggests that a subset of N1 pa-
tients with high risk of LR may benefit from further local
treatment after surgery. The purpose of the present
study was to assess the clinical and pathological risk fac-
tors that influence LR in patients with resected N1
NSCLC in order to identify and select those patients at
high risk of LR for further studies on PORT.
Methods
Study population
This retrospective medical record review study was ap-
proved by our institutional review board. The inclusion
criteria were as follows: (1) pathologically confirmed
T1–3N1M0 NSCLC, (2) consecutive treatment between
January 2007 and December 2008 in our hospital, (3)
anatomical pulmonary resection with lobecotomy, sleeve
lobectomy, bilobecotomy or pneumonectomy and (4)
complete records of clinical and pathological data. The
exclusion criteria were as follows: (1) positive surgical
margins, (2) prior neoadjuvant therapy involving chemo-
therapy, radiotherapy or PORT, (3) synchronous primary
lung tumors or a history of lung cancer and (4) peri-
operative death. Patients were staged according to the
7th edition of the American Joint Committee on Cancer
(AJCC) tumor-node-metastasis (TNM) classification sys-
tem [12].
Definition of recurrence
The primary end point of this study was freedom from
LR (FFLR). Local recurrence was defined as the recur-
rence of a tumor at the bronchial stump or anastomosis,and regional recurrence was defined as recurrence in the
mediastinum, hilum or supraclavicular fossa. Other sites
of recurrence, including contralateral lung and meta-
static lymph nodes in the neck or axilla were defined as
distant metastasis (DM). Concurrent recurrence was de-
fined as LR and DM being detected within 30 days of
each other; otherwise, it was considered sequential
recurrence.
The diagnosis of disease recurrence and recurrence
sites was based on a review of the medical records, in-
cluding operative notes, follow-up imaging reports and
cytological and pathological reports. All local recur-
rences were confirmed by sputum cytology or broncho-
scopic biopsy. Nodal recurrences were confirmed by
biopsy using ultrasound-guided fine-needle aspiration
(FNA) or endobronchial ultrasound-guided transbron-
chial needle aspiration (EBUS-TBNA). New or enlarging
lymph nodes (≥1 cm short axis) were confirmed by com-
puted tomography (CT) or through hypermetabolism on
positron-emission tomography (PET)-CT, which was
found to be consistent with disease progression during
subsequent clinical follow-ups. Sites of recurrent lymph
nodes were identified using the lymph node map pro-
posed by the International Association for the Study of
Lung Cancer (IASLC) [13].
Follow-up
The median follow-up time was 53.8 months (range,
1.4–81.8 months). Physical examination, chest x-rays
and/or CT scans and abdominal ultrasonography were
performed every 3 months for the first 2 years following
adjuvant chemotherapy, then every 6 months for 5 years
and every year thereafter. PET-CT was performed if re-
current disease could not be identified or suspected by
routine CT. Other tests were carried out at the discre-
tion of the treating physician.
Of the 199 patients that were eligible for this study,
158 (79.4%) had received adjuvant platinum-based
chemotherapy after surgery.
OS was measured from the date of surgery to the date
of death from any cause; disease-free survival (DFS) was
measured from the date of surgery to the date of LR,
DM or death from any cause; FFLR was measured from
the date of surgery to the date of identification of LR;
freedom from DM (FFDM) was measured from the date
of surgery to the date of identification of DM.
Statistical analysis
The Kaplan-Meier method was used to estimate OS,
DFS, FFLR and FFDM. Differences between groups were
calculated using the log-rank test. Receiver operating
characteristic (ROC) curves were constructed, and the
Youden Index was used to determine the optimal cut-off
points for part of continuous variables, suh as number
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ate and multivariate Cox regression analyses were per-
formed to assess risk factors associated with LR. A P-
value <0.05 was considered statistically significant.
Results
Patient characteristics
Patient characteristics and treatments are given in
Table 1. The median number of dissected lymph nodes
was 21 (range, 3–66). The median number of metastatic
lymph nodes was 2 (range, 1–8). The number of dis-
sected mediastinal lymph node (MLN) stations was eval-
uated from both surgical records and pathological
reports; however, some of the results were inconsistent:
78 patients had <3 MLNs recorded in both reports; 86
patients had ≥3 MLNs recorded in both reports; and 35
patients had ≥2 dissected MLN stations recorded in
their surgical records but <3 in their pathological
reports.
The 3- and 5-year OS rates were 78.4% and 65.6%, re-
spectively, and the corresponding DFS rates were 55.3%
and 45.7%, respectively (Figure 1). The 3-year and 5-year
FFLR and FFDM rates were 80.8% and 77.3%, respect-
ively and 65.9% and 57.4%, respectively (Figure 2).
Tumor recurrence occurred in 95 patients (47.7%) by
the last follow-up.
LR and DM were identified in 41 patients (20.6%) and
79 patients (39.7%), respectively (Figure 3). Concurrent
LR and DM were identified in 25 patients (12.6%). Lung
and pleura were the most common sites of DM (40 pa-
tients and 11 patients, respectively). Other DM sites
were the brain (24 patients, 12.1%), bone (25 patients,
12.6%), liver (9 patients, 4.5%) and adrenal gland (4 pa-
tients, 2.0%).
Risk factors for LR
We evaluated patients’ clinical and pathological charac-
teristics by univariate and multivariate analyses to iden-
tify factors that might be associated with FFLR (Table 1).
The optimal cut-off points for the number of dissected
lymph nodes and lymph node ratio (LNR) in relation to
LR were determined by constructing ROC curves and
calculating the maximal Youden index. Complete MLN
dissection and examination (CMD) and incomplete
MLN dissection or examination (IMD) were defined ac-
cording to the number of MLN stations recorded in the
surgical records and pathological reports. CMD was de-
fined as ≥3 MLNs in both reports with a 5-year FFLR of
89%; IMD was defined as either <3 MLNs in both re-
ports with a 5-year FFLR of 68.6% or as ≥3 MLNs in the
surgical records and <3 MLNs in the pathological re-
ports with a 5-year FFLR of 68%.
Univariate analyses identified the following factors as
being associated with a lower FFLR rate: nonsmokers(P = 0.026), ≤23 dissected lymph nodes (P = 0.007), vis-
ceral pleural invasion (P = 0.025), LNR >10% (P = 0.027);
positive lymph nodes at station 10 (P = 0.01; Figure 4)
and IMD (P = 0.001; Figure 5). Other risk factors that
showed a trend of lower FFLR included lymphovascular
invasion (P = 0.088) and negative bronchoscopy findings
(P = 0.08).
Multivariate analyses showed that positive lymph
nodes at station 10 (hazard ratio [HR], 0.527; 95% confi-
dence interval [CI], 0.281–0.989; P = 0.046) and IMD
(HR, 0.309; 95% CI, 0.142–0.671; P =0.003) were associ-
ated with a lower FFLR.
A combined model was generated to evaluate the LR
in patents at different risk levels, based on the number
of identified risk factors. The 3- and 5-year FFLR rates
were as follows: in patients with negative lymph nodes
at station 10 and CMD (n = 69), the rates were 90.1%
and 88.1%, respectively; in patients with positive lymph
nodes at station 10 and CMD (n = 17), the rates were
93.3% and 93.3%, respectively; in patients with negative
lymph nodes at station 10 and IMD (n = 76), the rates
were 81% and 75.9%, respectively; and in patients with
positive lymph nodes at station 10 and IMD (n = 37), the
rates were considerably lower at 55.7% and 52%, respect-
ively. The differences in FFLR between patients with
one, both or neither of these risk factors were statisti-
cally significant (P = 0.000; Figure 6).
Discussion
The LR rate in patients with resected N1 NSCLC is re-
ported to be 9%–46% (Table 2). In comparison, our data
showed a 5-year LR rate of 22.7%. LR risk may now be
higher as adjuvant chemotherapies can reduce or delay
DM and thereby increase survival times. In addition,
better LR control has been associated with improved OS
in locally advanced NSCLC patients [14,15], indicating
that a decreased LR rate after surgery might also im-
prove OS, which suggests that PORT could be beneficial
in patients with resected N1 NSCLC who are at high
risk for LR.
To date, studies on PORT have found no survival ben-
efits for patients with resected N1 NSCLC, and there-
fore, PORT is not recommended for these patients.
Moreover, compared with chemotherapy alone, PORT
following adjuvant chemotherapy was found to be asso-
ciated with detrimental survival in N1 disease patients in
the Adjuvant Navelbine International Trialist Associ-
ation (ANITA) randomized study [7]. The ANITA trial
was a randomized study, but the patients that were rec-
ommended for PORT were selected by the researchers,
so were not randomized [7]; consequently, patient selec-
tion bias may have been introduced into the results.
A meta-analysis has also reported similar detrimental
effects of PORT in N1 NSCLC patients [8]; however,
Table 1 Results of univariate and multivariate analyses of risk factors for freedom from locoregional recurrence in
patients with resected N1 non–small cell lung cancer
Patient characteristics and treatments No. of patients Univariate analysis FFLR (%) Multivariate analysis
3-yr 5-yr P χ2 P HR (95% CI)
Sex
Male 164 81.2 78.1 0.934 0.007
Female 35 78 72.4
Age (yrs)
<65 144 79 78.2 0.942 0.005
≥65 55 85.6 74.7
Smoking history
No 143 69 66.6 0.026 4.958 0.388 0.735 (0.365–1.479)
Yes 56 85.3 81.5
Diabetes
No 184 80.8 77 0.787 0.073
Yes 15 80 80
Tumor type
Peripheral 89 78.5 74.1 0.267 1.233
Central 110 82.4 79.9
Location
Upper 114 78.5 77.4 0.868 0.028
Middle/lower lobe 85 83.8 77.3
Laterality
Left 103 81 81 0.243 1.363
Right 96 80.5 73.7
Surgical procedure
Pneumonectomy 54 83.1 80.3 0.662 0.191
Lobectomy 145 79.9 76.2
Histology
Squamous cell 101 81.8 80.5 0.201 1.633
Non-squamous cell 98 79.3 73.2
Tumor differentiation
Well/Moderate 156 80.1 75.3 0.497 0.462
Poor 43 81.6 73.9
Pathological stage
T1 63 81.4 77.5 0.935 0.135
T2 92 79.9 78.5
T3 44 81.4 74.2
Tumor size
≤5 cm 147 82.6 79.9 0.214 1.545
>5 cm 52 75.3 70
Visceral pleural invasion
No 82 88 86.3 0.025 5.025 0.075 1.882 (0.937–3.778)
Yes 117 75.7 71
LVI
No 145 83.6 79.9 0.088 2.905 0.213 1.506 (0.79–2.869)
Yes 54 72.9 69.6
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Table 1 Results of univariate and multivariate analyses of risk factors for freedom from locoregional recurrence in
patients with resected N1 non–small cell lung cancer (Continued)
Bronchoscopy
Negative/not done 88 77.3 72.7 0.080 3.063 0.721 0.873 (0.415–1.836)
Positive 111 83.5 81.1
Adjuvant chemotherapy
No 41 86.1 75.3 0.975 0.001
Yes 158 79.5 77.9
No. of dissected LNs
≤23 121 74.4 71.1 0.007 7.981 0.14 0.539 (0.238–1.224)
>23 78 91.1 87.6
No. of metastatic LNs
1 88 83.5 82 0.182 1.785
≥2 111 78.7 73. 7
LNR
≤10% 119 86.6 84.1 0.027 4.871 0.976 1.011 (0.506–2.017)
>10% 80 73.8 69.1
Dissection of MLN
IMD 113 73.2 68.5 0.001 11.58 0.003 0.309 (0.142–0.671)
CMD 86 90.7 89 1
No. of metastatic LN stations
1 138 81.7 79.9 0.154 2.032
≥2 61 78.4 70.5
Positive LNs at station 10
Yes 54 68.5 65.9 0.01 6.724 0.046 0.527 (0.281–0.989)
No 145 85.3 81.7
FFLR, freedom from locoregional recurrence; HR, hazard ratio; CI, confidence interval; LVI, lymphovascular invasion; LN, lymph node; LNR, lymph node ratio; MLN,
mediastinal lymph node; CMD, complete MLN dissection and examination; IMD, incomplete MLN node dissection or examination.
Figure 1 Survival rates of patients with resected N1 non–small
cell lung cancer. The Kaplan-Meier curves show the decline in overall
survival (OS) and disease-free survival (DFS) rates following surgery. The
follow-up periods were 1.4–81.8 months (median, 53.8 months).
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mental in all patients with N1 disease. The trials in-
cluded in the meta-analysis had been carried out using
older radiation techniques, such as those that delivered
doses using wedges with opposed lateral portals with an
excessive volume; used different fractionation schedules
ranging from 1.8–3.0 Gy; used different total doses
ranging from 30–60 Gy; or used cobalt-60, which has
a worse biological efficacy and therapeutic ratio than
those achieved with current linear accelerators [16-19].
Treatment-related morbidities and deaths were more
prevalent with these outdated radiation techniques than
with more modern techniques, which may account for
the detrimental survival rates. This has been supported
by two recent randomized trials on NSCLC, which in-
vestigated PORT with modern radiation techniques. The
first showed that PORT was associated with lower LR
and higher 5-year OS in patients with postoperative
pathological N0 NSCLC [20]; the other found that
PORT with modern techniques significantly reduced LR,
although there no significant improvement in OS and DFS
was observed in patients with postoperative pathological
Figure 4 Comparison between patients with positive and
negative lymph nodes at station 10. The difference in freedom
from locoregional recurrence (FFLR) rates between patients with
resected N1 non–small cell lung cancer and positive or negative
lymph nodes (LNs) at station 10 is significant (P = 0.01), showing that
a positive LN at station 10 is a risk factor for LR.
Figure 2 Freedom from locoregional recurrence and freedom
from distant metastasis rates. The Kaplan-Meier curves show freedom
from locoregional recurrence (FFLR) and freedom from distant
metastasis (FFDM) rates for patients with resected N1 non–small
cell lung cancer following surgery.
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was acceptable in both these trials. These findings suggest
that PORT based on modern technologies may promote
therapeutic efficacy and could be beneficial for patients
with resected pathological N1 NSCLC who are at high risk
for LR.
To our knowledge, our present study is the first to
identify and report that IMD and positive lymph nodes
at station 10 may be risk factors for LR in patients with
resected N1 NSCLC, and as such, these patients may
warrant further attention. Patients with positive lymph
nodes at station 10 are at a higher risk for micrometastasesFigure 3 Pattern of locoregional recurrence and distant
metastasis. The Venn diagram reflects the pattern of locoregional
recurrence (LR; left), distant metastasis (DM; right) and concurrent LR
and DM (intersection) among the patients in the study group with
resected N1 non–small cell lung cancer.in MLNs through the lymphatic drainage pathway of
NSCLC. Studies have reported that the number of
resected lymph nodes and the extent of dissected lymph
node stations were associated with survival in patients
with resectable NSCLC [22-24]. Several studies have rec-
ommended that at least six lymph nodes from three MLN
stations should be excised [23,25,26]; however, others rec-
ommend resection of at least six lymph nodes from medi-
astinal stations and station 10 for accurate nodal staging
and prediction of prognosis in patients with resected NIFigure 5 Comparison between patients with incomplete and
complete mediastinal lymph node dissection and examination.
The difference in freedom from locoregional recurrence (FFLR) rates
between patients with complete mediastinal lymph node (MLN)
dissection and examination (CMD) and incomplete MLN dissection
or examination (IMD) is significant (P = 0.01), and shows that IMD is
a greater risk factor for LR than positive lymph nodes at station 10 in
patients with resected N1 non–small cell lung cancer.
Figure 6 Comparison of freedom from locoregional recurrence
in patients with different risk factors. Comparison of freedom
from locoregional recurrence (FFLR) in patients with resected N1
non–small cell lung cancer and either complete mediastinal lymph
node (MLN) dissection and examination (CMD) or incomplete MLN
dissection or examination (IMD), and negative lymph nodes (LNs) at
station 10 or positive LNs at station 10, shows that those most at risk
for LR have both IMD and positive LNs at station 10.
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that the extent of dissected or examined MLN stations
may be significantly associated with LR and verify the
importance of performing sufficient MLN dissections or
examinations.
In this study, we found that patients with resected NI
NSCLC and <3 dissected or examined MLN stations had
lower FFLR rates than those with ≥3 dissected and
examinated MLN stations. Furthermore, our findings
showed that the 5-year FFLR rate in patients with IMD
(75.9%) was worse than that observed in patients with
positive lymph nodes at station 10 (93.3%), indicating
that IMD was the greater risk factor for LR (Figure 6).
Patients with both risk factors had the highest 5-year LR
rate (48%), which was comparable to reported values in
resected N2 NSCLC [29]; these patients should there-
fore be recommended PORT. In contrast, patients with
IMD alone should only be considered for PORT afterTable 2 Risk factors for locoregional recurrence (LR) and distan
cell lung cancer (NSCLC)
Author n CT (%) 5-yr actuarial DM (%) 5-yr actuarial LR
Saynak [34] 335 8 23 (crude) 35
Higgins [36] 198 25 55 40
Varlotto [38] 60 40 32 46
Sawyer [30] 107 0 47 38
Lopez Guerra [33] 1402 9 16 9
Fujimoto [37] 180 NM 23 (crude) 22 (crude)
This study 199 79.4 42.6 22.7
LR, locoregional recurrence; DM, distant metastasis; LVI, lymphovascular invasion; V
lymph node; NM, not mentioned.
Comparisons between LR and DM rates for previously reported risk factors and thocareful consultation between the surgeon and radiation
oncologist.
Tumor size has been shown to be a prognostic factor
for survival in patients with NSCLC [30-32]. Saynak
et al. and Lopez Guerra et al. reported that tumor size
was independently associated with LR in resected N1
NSCLC patients [33,34]. Other reports include three
studies which found that lymphovascular invasion was a
risk factor for LR in N1 NSCLC patients [33-35]. How-
ever, in the study by Lopez Guerra et al. [33], the num-
ber of patients with N1 NSCLC was small (16%)
compared to the total sample population, and the 5-year
LR was much lower (9%) than those reported in previous
studies. Several studies have reported visceral pleural in-
vasion as a risk factor for LR [33,36,37], and Varlotto
et al. observed an increased risk of LR following adju-
vant chemotherapy [38]. Surgical procedures, such as
lobectomy or pneumonectomy and positive preoperative
bronchoscopy have also been associated with a risk of
LR in N1 NSCLC patients [30,35,39]. However, these re-
ports are inconsistent, and their findings will need fur-
ther confirmation before being used in patient selection
for PORT in N1 NSCLC.
Our retrospective study had the following limitations:
It was a single-institution study, and therefore may have
had patient selection bias. Some of the patients under-
went insufficient MLN dissection or examination, and
may have been staged with N2 disease if they had under-
gone sufficient MLN dissection, which could have intro-
duced staging bias. Patients with concurrent LR and DM
may not accurately reflect the pattern of failure observed
in this study, and LR that developed before or after DM
may not have been identified promptly due to occult
symptoms or incomplete radiologic examination. Despite
these limitations, our findings support further investiga-
tions on the role of PORT in patients with resected N1
NSCLC who have the risk factors for LR identified in
this study.t metastasis (DM) in patients with resected N1 non–small
(%) Risk factors for LR
LVI; tumor size
Visceral pleural invasion; VATS approach; no. of involved N1 nodes
Chemotherapy
Positive preoperative bronchoscopy findings
Surgical procedure; LVI; visceral pleural invasion; tumor size
Visceral pleural invasion
Incomplete MLN dissection; positive LN at station 10
ATS, video-assisted thoracic surgery; LN, lymph node; MLN, mediastinal
se reported in our study.
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The incidence of LR in patients with surgically resected
T1–3N1M0 NSCLC is high. Patients with both IMD and
positive lymph nodes at station 10 are at the highest risk
for LR, and potentially, the most likely to benefit from
adjuvant PORT. Our findings indicate that further inves-
tigation of PORT is warranted in this subset of N1
NSCLC patients.
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